In the present study, we conducted comprehensive research on SESN2 expression in glioma and evaluated its potential as a prognostic biomarker based on the TCGA database, and explore the role of related immune cells in glioma and possible molecular pathways. The gene discussed is SESN2; the disease is central nervous system cancer.